• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Amplyx - Articles and news items

epr-logo

Amplyx initiates dosing in antifungal Phase I trial for the treatment of life-threatening infections

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +